| scholarly article | Q13442814 |
| P2093 | author name string | Mary Jo Lechowicz | |
| Pamela B Allen | |||
| P2860 | cites work | Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type | Q45362672 |
| Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia | Q46738245 | ||
| Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma | Q48517891 | ||
| Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL. | Q50900532 | ||
| Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. | Q50960230 | ||
| Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. | Q51403316 | ||
| Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood a | Q63384236 | ||
| Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters | Q82045898 | ||
| Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma | Q82107025 | ||
| Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma | Q82798869 | ||
| First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma | Q84587303 | ||
| Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States | Q88645165 | ||
| Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy | Q88693525 | ||
| DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China | Q89148943 | ||
| The optimal timing of radiotherapy in the combined modality therapy for limited-stage extranodal NK/T cell lymphoma (ENKTL): a systematic review and meta-analysis | Q91056004 | ||
| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations | Q29615392 | ||
| Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project | Q33382121 | ||
| SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. | Q33402956 | ||
| Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma | Q33423854 | ||
| Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial | Q33425005 | ||
| CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China | Q33655362 | ||
| Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type | Q33677463 | ||
| Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study | Q34890484 | ||
| Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. | Q35006668 | ||
| Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. | Q35010999 | ||
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | Q35068768 | ||
| Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs | Q36757012 | ||
| Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma | Q37301747 | ||
| Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma | Q37321943 | ||
| Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States | Q37350788 | ||
| Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008) | Q37709190 | ||
| Allogeneic transplantation in T-cell lymphomas | Q38182256 | ||
| Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. | Q38426101 | ||
| The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods | Q38450591 | ||
| Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population | Q38835470 | ||
| Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy | Q39038225 | ||
| A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis | Q39999898 | ||
| Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease | Q40040761 | ||
| CD52 expression in non-mycotic T- and NK/T-cell lymphomas | Q40239088 | ||
| PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. | Q40336693 | ||
| Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma | Q40441775 | ||
| CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type | Q41085075 | ||
| A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-ce | Q41472982 | ||
| High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation | Q42146630 | ||
| Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients | Q42202511 | ||
| Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type | Q42267458 | ||
| Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis | Q43905021 | ||
| Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study | Q45069595 | ||
| P433 | issue | 10 | |
| P921 | main subject | extranodal NK/T-cell lymphoma, nasal type | Q4763254 |
| P304 | page(s) | 513-520 | |
| P577 | publication date | 2019-10-01 | |
| P1433 | published in | Journal of Oncology Practice | Q6295683 |
| P1476 | title | Management of NK/T-Cell Lymphoma, Nasal Type | |
| P478 | volume | 15 |
Search more.